{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T17:35:07Z","timestamp":1795196107457,"version":"4.10.3"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Opioids remain the mainstay of cancer pain management but are associated with systemic toxicity. In refractory cancer pain, intrathecal therapy (ITT) is associated with improved pain control, reduced systemic side effects, and improved survival. It has been assumed that ITT decreases systemic serum opioid levels and their associated toxicity, but there are limited data to support this assumption. This study hypothesizes that serum opioid levels decrease with ITT. Secondary objectives include comparative measures of pain, bowel function, and other cancer-related symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>Fifty-one cancer patients undergoing ITT for cancer pain were recruited in a prospective observational study. Daily oral morphine equivalency (OME) dose, serum opioid levels, Brief Pain Inventory (BPI), MD Anderson Symptom Inventory (MDASI), and a constipation questionnaire were obtained at the time of implant, and 4 and 8 weeks postoperatively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Average baseline daily OME was 375 mg (median, 240; interquartile range, 150\u2013405; range, 0\u20133160), mean serum morphine concentration was 53.7 ng\/mL (n = 17), and mean oxycodone concentration was 73.7 ng\/mL (n = 20). At 4 weeks, 87.5% of patients had discontinued non-IT opioids, and 53% had undetectable (&lt;2 ng\/mL) serum opioid concentrations. At 8 weeks, 92% remained off all non-IT opioids and 59% had undetectable serum opioid levels. IT morphine doses &gt;4.2 mg\/d were invariably associated with detectable serum levels; with doses &lt;4.2 mg, morphine was undetectable in 80% of subjects. IT hydromorphone doses &gt;6.8 mg\/d were detectable in the serum. Using linear mixed model analyses, there were statistically significant decreases in the mean \u201cworst pain,\u201d \u201caverage pain,\u201d and MD Anderson symptom severity and interference scores at 4 and 8 weeks. This change was independent of serum opioid levels; when analyzed separately, there was no difference in the pain scores of subjects with detectable serum opioid levels compared to those with undetectable levels at 4 and 8 weeks. Constipation ranked as \u201cquite a bit\u201d or \u201cvery much\u201d decreased from 58.7% to 19.2% of subjects at week 4 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001) and to 37.5% at 8 weeks (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .23). A very low complication rate was observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>ITT for cancer pain was associated with a marked reduction in serum opioid concentrations, with the majority of patients having undetectable serum levels. Reducing serum opioid concentrations in cancer patients may have implications with respect to restoring bowel function, improving fatigue, and promoting the integrity of antitumor immune function and warrants further study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1213\/ane.0000000000004276","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T07:06:59Z","timestamp":1560755219000},"page":"1035-1044","source":"Crossref","is-referenced-by-count":37,"title":["Prospective Association of Serum Opioid Levels and Clinical Outcomes in Patients With Cancer Pain Treated With Intrathecal Opioid Therapy"],"prefix":"10.1213","volume":"130","author":[{"given":"Shane E.","family":"Brogan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill E.","family":"Sindt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina M.","family":"Jackman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Wilding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Okifuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230721","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0304-3959(01)00324-4","article-title":"Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology.","volume":"93","author":"Meuser","year":"2001","journal-title":"Pain"},{"key":"R2-20230721","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1067\/S1526-5900(03)00730-2","article-title":"Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain.","volume":"4","author":"Rauck","year":"2003","journal-title":"J Pain"},{"key":"R3-20230721","doi-asserted-by":"crossref","first-page":"992","DOI":"10.6004\/jnccn.2013.0119","article-title":"Adult cancer pain.","volume":"11","author":"Swarm","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"R4-20230721","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/j.1526-4637.2011.01262.x","article-title":"Patient-controlled intrathecal analgesia for the management of breakthrough cancer pain: a retrospective review and commentary.","volume":"12","author":"Brogan","year":"2011","journal-title":"Pain Med"},{"key":"R5-20230721","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1200\/JCO.2002.02.118","article-title":"Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival.","volume":"20","author":"Smith","year":"2002","journal-title":"J Clin Oncol"},{"key":"R6-20230721","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/annonc\/mdi156","article-title":"An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM).","volume":"16","author":"Smith","year":"2005","journal-title":"Ann Oncol"},{"key":"R7-20230721","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1213\/ANE.0000000000002903","article-title":"Intrathecal drug delivery systems for refractory pancreatic cancer pain: observational follow-up study over an 11-year period in a comprehensive cancer center.","volume":"126","author":"Carvajal","year":"2018","journal-title":"Anesth Analg"},{"key":"R8-20230721","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/pme.12060","article-title":"A cost utilization analysis of intrathecal therapy for refractory cancer pain: identifying factors associated with cost benefit.","volume":"14","author":"Brogan","year":"2013","journal-title":"Pain Med"},{"key":"R9-20230721","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/AAP.0000000000000251","article-title":"Prospective observational study of patient-controlled intrathecal analgesia: impact on cancer-associated symptoms, breakthrough pain control, and patient satisfaction.","volume":"40","author":"Brogan","year":"2015","journal-title":"Reg Anesth Pain Med"},{"key":"R10-20230721","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/ner.12538","article-title":"The Polyanalgesic Consensus Conference (PACC): recommendations on intrathecal drug infusion systems best practices and guidelines.","volume":"20","author":"Deer","year":"2017","journal-title":"Neuromodulation"},{"key":"R11-20230721","first-page":"93","article-title":"Economic burden of opioid-induced constipation among long-term opioid users with noncancer pain.","volume":"8","author":"Wan","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"R12-20230721","first-page":"160","article-title":"Increased burden of healthcare utilization and cost associated with opioid-related constipation among patients with noncancer pain.","volume":"9","author":"Fernandes","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"R13-20230721","first-page":"79","article-title":"Comparing healthcare utilization and costs among Medicaid-insured patients with chronic noncancer pain with and without opioid-induced constipation: a retrospective analysis.","volume":"10","author":"Olufade","year":"2017","journal-title":"Am Health Drug Benefits"},{"key":"R14-20230721","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/03007995.2017.1358702","article-title":"The prevalence of constipation at admission and after 1 week of palliative care: a multi-center study.","volume":"34","author":"Mercadante","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"R15-20230721","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.pain.2004.09.019","article-title":"Opioids in chronic non-cancer pain: systematic review of efficacy and safety.","volume":"112","author":"Kalso","year":"2004","journal-title":"Pain"},{"key":"R16-20230721","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/BRS.0000000000001733","article-title":"Intrathecal versus intravenous morphine in minimally invasive posterior lumbar fusion: a blinded randomized comparative prospective study.","volume":"42","author":"Araimo Morselli","year":"2017","journal-title":"Spine (Phila Pa 1976)"},{"key":"R17-20230721","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrclinonc.2014.127","article-title":"Cancer-related fatigue\u2013mechanisms, risk factors, and treatments.","volume":"11","author":"Bower","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"R18-20230721","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jpainsymman.2017.11.026","article-title":"Impact of opioid therapy on sleep and respiratory patterns in adults with advanced cancer receiving palliative care.","volume":"55","author":"Good","year":"2018","journal-title":"J Pain Symptom Manage"},{"key":"R19-20230721","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/cncr.28434","article-title":"Prevalence and characteristics of moderate to severe fatigue: a multicenter study in cancer patients and survivors.","volume":"120","author":"Wang","year":"2014","journal-title":"Cancer"},{"key":"R20-20230721","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","article-title":"Increases in drug and opioid-involved overdose deaths - United States, 2010-2015.","volume":"65","author":"Rudd","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R21-20230721","first-page":"1","article-title":"Drug overdose deaths in the United States, 1999\u20132016.","volume":"294","author":"Hedegaard","year":"2017","journal-title":"NCHS Data Brief"},{"key":"R22-20230721","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1213\/ANE.0b013e3182645dfd","article-title":"Characteristics of distribution of morphine and metabolites in cerebrospinal fluid and plasma with chronic intrathecal morphine infusion in humans.","volume":"115","author":"Wallace","year":"2012","journal-title":"Anesth Analg"},{"key":"R23-20230721","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1213\/ANE.0b013e3182536211","article-title":"The frequency and magnitude of cerebrospinal fluid pulsations influence intrathecal drug distribution: key factors for interpatient variability.","volume":"115","author":"Hsu","year":"2012","journal-title":"Anesth Analg"},{"key":"R24-20230721","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10928-010-9184-y","article-title":"Understanding pharmacokinetics using realistic computational models of fluid dynamics: biosimulation of drug distribution within the CSF space for intrathecal drugs.","volume":"37","author":"Kuttler","year":"2010","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"R25-20230721","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1210\/jcem.85.6.6615","article-title":"Endocrine consequences of long-term intrathecal administration of opioids.","volume":"85","author":"Abs","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R26-20230721","doi-asserted-by":"crossref","first-page":"e002856","DOI":"10.1136\/bmjopen-2013-002856","article-title":"Hypogonadism and low bone mineral density in patients on long-term intrathecal opioid delivery therapy.","volume":"3","author":"Duarte","year":"2013","journal-title":"BMJ Open"},{"key":"R27-20230721","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/00000542-199509000-00008","article-title":"Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers.","volume":"83","author":"Yeager","year":"1995","journal-title":"Anesthesiology"},{"key":"R28-20230721","first-page":"4491","article-title":"Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth.","volume":"62","author":"Gupta","year":"2002","journal-title":"Cancer Res"},{"key":"R29-20230721","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/00000539-200006000-00028","article-title":"The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients.","volume":"90","author":"Sacerdote","year":"2000","journal-title":"Anesth Analg"},{"key":"R30-20230721","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/00000542-200610000-00008","article-title":"Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis?","volume":"105","author":"Exadaktylos","year":"2006","journal-title":"Anesthesiology"},{"key":"R31-20230721","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1213\/ane.0b013e3181770f55","article-title":"Long-term survival after colon cancer surgery: a variation associated with choice of anesthesia.","volume":"107","author":"Christopherson","year":"2008","journal-title":"Anesth Analg"},{"key":"R32-20230721","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/ALN.0b013e31817f5b73","article-title":"Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis.","volume":"109","author":"Biki","year":"2008","journal-title":"Anesthesiology"},{"key":"R33-20230721","doi-asserted-by":"crossref","first-page":"e7519","DOI":"10.1097\/MD.0000000000007519","article-title":"Effects of oxycodone on immune function in patients undergoing radical resection of rectal cancer under general anesthesia.","volume":"96","author":"Cui","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R34-20230721","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF03020942","article-title":"Intrathecal morphine suppresses NK cell activity following abdominal surgery.","volume":"47","author":"Yokota","year":"2000","journal-title":"Can J Anesth"},{"key":"R35-20230721","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.intimp.2010.06.016","article-title":"Long-term intrathecal morphine and bupivacaine upregulate MOR gene expression in lymphocytes.","volume":"10","author":"Campana","year":"2010","journal-title":"Int Immunopharmacol"},{"key":"R36-20230721","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3109\/00207459108985455","article-title":"Evaluation of NK and LAK cell activities in neoplastic patients during treatment with morphine.","volume":"59","author":"Provinciali","year":"1991","journal-title":"Int J Neurosci"}],"container-title":["Anesthesia &amp; Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000004276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:23:38Z","timestamp":1786112618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000004276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0000000000004276","relation":{},"ISSN":["0003-2999"],"issn-type":[{"value":"0003-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}